Top

American Journal of Clinical Dermatology

Published in:

01-03-2021 | Infliximab | Commentary

Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Authors: Tasnim Abdalla, Michelle A. Lowes, Nirmal Kaur, Robert G. Micheletti, A. Hillary Steinhart, Afsaneh Alavi

Published in: American Journal of Clinical Dermatology | Issue 2/2021

Abstract

Tumor necrosis factor-α inhibitors, adalimumab and infliximab, are at the forefront of biologic therapy for the management of moderate-to-severe hidradenitis suppurativa, with adalimumab as currently the only approved medication for this condition. In treating patients, primary or secondary lack of response (also termed suboptimal response) is a major burden for both patients and healthcare systems and is a challenge with biologics in part owing to the development of anti-drug antibodies following treatment. To overcome this, therapeutic drug monitoring may be conducted proactively or reactively to a patient’s suboptimal response guided by measurements of trough serum drug concentrations and levels of anti-drug antibodies. While strong evidence to support the utility of therapeutic drug monitoring exists in patients with inflammatory bowel disease, current information is limited in the context of hidradenitis suppurativa. We sought to summarize the available evidence and to present the role of therapeutic drug monitoring and other dose optimization strategies in improving clinical response in patients with hidradenitis suppurativa treated with tumor necrosis factor-α inhibitors.

Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73:S82–8. https://doi.org/10.1016/j.jaad.2015.07.053.CrossRefPubMed

Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization: systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33:19–31. https://doi.org/10.1111/jdv.15233.CrossRefPubMed

Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–34. https://doi.org/10.1056/NEJMoa1504370.CrossRefPubMed

Kirsten N, Petersen J, Hagenström K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany: an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174–9.CrossRef

Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412–9.CrossRef

Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.CrossRef

Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 1):191–4.CrossRef

Jemec GBE, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73:S4–7.CrossRef

Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation: systematic review and meta-analysis. Biomed Dermatol. 2020;4:2. https://doi.org/10.1186/s41702-019-0052-0.CrossRef

10.

Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–52. https://doi.org/10.1111/bjd.12104.CrossRefPubMed

11.

Savage KT, Flood KS, Porter ML, Kimball AB. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:1–12. https://doi.org/10.1177/2040622319851640.CrossRef

12.

Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846–55. https://doi.org/10.7326/0003-4819-157-12-201212180-00004.CrossRefPubMed

13.

Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17. https://doi.org/10.1016/j.jaad.2009.06.050.CrossRefPubMed

14.

Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989–94. https://doi.org/10.1111/jdv.13216.CrossRefPubMed

15.

Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–42. https://doi.org/10.1111/bjd.13270.CrossRefPubMed

16.

Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A. Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series. Am J Clin Dermatol. 2020. https://doi.org/10.1007/s40257-020-00575-3.CrossRefPubMed

17.

Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15:201–11.PubMed

18.

Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019;181:314–23. https://doi.org/10.1111/bjd.17641.CrossRefPubMedPubMedCentral

19.

Bagel J, Lebwohl M, Israel RJ, Jacobson A. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020;82:344–51. https://doi.org/10.1016/j.jaad.2019.05.094.CrossRefPubMed

20.

Zhou J, Limsakun T, Yin O, et al. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of an oral formulation of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. J Clin Pharmacol. 2019;59:1669–77. https://doi.org/10.1002/jcph.1474.CrossRefPubMed

21.

Mojtahed Poor S, Ulshöfer T, Gabriel LA, et al. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. Clin Exp Immunol. 2019;196:259–75. https://doi.org/10.1111/cei.13261.CrossRefPubMedPubMedCentral

22.

Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56:1091–102. https://doi.org/10.1007/s40262-016-0502-4.CrossRefPubMed

23.

Zouboulis CC, Desai N, Emtestam L, Schneider-Burrus S, Szepietowski JC, Zee HH, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44. https://doi.org/10.1111/jdv.12966.CrossRefPubMed

24.

Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64. https://doi.org/10.1056/NEJMcp1014163.CrossRefPubMed

25.

Liu M, Degner J, Davis JW, Idler KB, Nader A, Mostafa NM, et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE. 2018;13:e0195325. https://doi.org/10.1371/journal.pone.0195325.CrossRefPubMedPubMedCentral

26.

Frew JW, Hawkes JE, Sullivan-Whalen M, Gilleaudeau P, Krueger JG. Inter-rater reliability of phenotypes and exploratory genotype–phenotype analysis in inherited hidradenitis suppurativa. Br J Dermatol. 2019;181:566–71. https://doi.org/10.1111/bjd.17695.CrossRefPubMedPubMedCentral

27.

Prens EP, Lugo-Somolinos AM, Paller AS, Kerdel F, Duan Y, Teixeira HD, et al. Baseline characteristics from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa (acne inversa) in clinical practice. Am J Clin Dermatol. 2020. https://doi.org/10.1007/s40257-020-00504-4.CrossRefPubMedPubMedCentral

28.

Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res. 2017;6:1272. https://doi.org/10.12688/f1000research.11337.1.CrossRefPubMedPubMedCentral

29.

Witte-Händel E, Wolk K, Tsaousi A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Investig Dermatol. 2019;139:1294–305. https://doi.org/10.1016/j.jid.2018.11.018.CrossRefPubMed

30.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517. https://doi.org/10.1038/ajg.2018.27.CrossRefPubMed

31.

Lichtenstein GR, Panaccione R, Mallarkey G. Efficacy and safety of adalimumab in Crohn’s disease. Ther Adv Gastroenterol. 2008;1:43–50. https://doi.org/10.1177/1756283X08092548.CrossRef

32.

Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31. https://doi.org/10.1053/j.gastro.2003.10.047.CrossRefPubMed

33.

Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490–501. https://doi.org/10.1093/ibd/izx072.CrossRefPubMedPubMedCentral

34.

Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Investig Dermatol. 2020. https://doi.org/10.1016/j.jid.2019.10.024.CrossRefPubMed

35.

Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. https://doi.org/10.1136/bmj.j2505.CrossRefPubMed

36.

Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60–9. https://doi.org/10.1016/j.jaad.2018.05.040.CrossRefPubMed

37.

Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094–101. https://doi.org/10.1016/j.jaad.2019.09.071.CrossRefPubMed

38.

Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa). Br J Dermatol. 2018;180:1009–17. https://doi.org/10.1111/bjd.17537.CrossRef

39.

HUMIRA (adalimumab) [package insert]. North Chicago (IL): Abb-Vie Inc.; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s409lbl.pdf. Accessed 05 Dec 2020.

40.

van der Zee H, Longcore M, Geng Z, Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020;34(5):1050–6. https://doi.org/10.1111/jdv.16023.CrossRefPubMed

41.

Bi Y, Liu J, Wang J, Epps RE, Kettl D, et al. Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J. 2019;21:91. https://doi.org/10.1208/s12248-019-0363-5.CrossRefPubMed

42.

National Institute for Clinical Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa. London: NICE; 2016. Technology appraisal no. 392. https://www.nice.org.uk/guidance/ta392. Accessed 22 Feb 2020.

43.

Gulliver W. Plenary lecture: updated medical treatments of hidradenitis suppurativa, more options, less evidence. Exp Dermatol. 2019;28(S2):5–55. https://doi.org/10.1111/exd.13893.CrossRef

44.

Alfageme F. Plenary lectures: intensification strategies 80 mg weekly with adalimumab in HS: when and what for? Exp Dermatol. 2019;28:5–55.CrossRef

45.

Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, Ferran M, Sánchez-Regaña M, Collgros H, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:56–60.CrossRef

46.

Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual JC, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa. Dermatology (Basel). 2020;236(1):25–30. https://doi.org/10.1159/000503606.CrossRef

47.

Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702–8. https://doi.org/10.1016/j.jaad.2019.05.022.CrossRefPubMed

48.

Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170:986–7.CrossRef

49.

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–34.CrossRef

50.

Laftah Z, Arkir Z, Agius E, Desai N. Abstract of "Main plenary session: infliximab for hidradenitis suppurativa; should we be measuring antibody levels?" Br J Dermatol. 2013;169(Suppl. 1): 1-7. https://doi.org/10.1111/bjd.12366.CrossRef

51.

Wang LL, Micheletti RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review. J Am Acad Dermatol. 2020;82:507–10. https://doi.org/10.1016/j.jaad.2019.09.012.CrossRefPubMed

52.

Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–68. https://doi.org/10.1016/j.cgh.2019.03.037.CrossRefPubMedPubMedCentral

53.

Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(522–30):522–30. https://doi.org/10.1016/j.cgh.2014.07.029.CrossRefPubMed

54.

Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–40. https://doi.org/10.1053/j.gastro.2009.07.062.CrossRefPubMed

55.

Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:1248–54. https://doi.org/10.1016/j.cgh.2006.06.025.CrossRefPubMed

56.

West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–6. https://doi.org/10.1111/j.1365-2036.2008.03828.x.CrossRefPubMed

57.

Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40:620–8. https://doi.org/10.1111/apt.12869.CrossRefPubMed

58.

Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–106. https://doi.org/10.1136/gutjnl-2019-318484.CrossRefPubMed

59.

Mitrev N, Van de Casteele N, Seow CH, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037–53. https://doi.org/10.1111/apt.14368.CrossRefPubMed

60.

Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–9. https://doi.org/10.1038/ajg.2010.9.CrossRefPubMedPubMedCentral

61.

Ward MG, Warner B, Unsworth N, et al. Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017;46:150–61. https://doi.org/10.1111/apt.14124.CrossRefPubMed

62.

Casteele NV, Ferrante M, Assche GV, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–9. https://doi.org/10.1053/j.gastro.2015.02.031.CrossRef

63.

Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology. 2019;157:985–96. https://doi.org/10.1053/j.gastro.2019.06.003.CrossRefPubMed

64.

Fernandes SR, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:263–70. https://doi.org/10.1093/ibd/izz131.CrossRefPubMed

65.

Freeman K, Taylor-Phillips S, Connock M, et al. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis. BMJ Open. 2017;7:014581. https://doi.org/10.1136/bmjopen-2016-014581.CrossRef

66.

Nakase H, Motoya S, Matsumoto T, DIAMOND Study Group, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46:873–82. https://doi.org/10.1111/apt.14318.CrossRefPubMedPubMedCentral

67.

Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–8. https://doi.org/10.1001/jama.2011.406.CrossRefPubMed

68.

Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease. J Gastroenterol. 2014;49:100–9. https://doi.org/10.1007/s00535-013-0803-4.CrossRefPubMed

69.

Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243–55. https://doi.org/10.1038/nrgastro.2013.253.CrossRefPubMed

70.

Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22:1999–2015. https://doi.org/10.1097/MIB.0000000000000772.CrossRefPubMed

71.

Cookson TA, Fedorak R, Halloran BP, et al. A157: the threshold for infliximab trough levels leading to dose escalation differs between Crohn’s disease and ulcerative colitis. J Can Assoc Gastroenterol. 2018;1:233–4. https://doi.org/10.1093/jcag/gwy009.157.CrossRefPubMedCentral

72.

Johnston A, Natarajan S, Hayes M, et al. Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol. BMJ Open. 2018;8:e019909. https://doi.org/10.1136/bmjopen-2017-019909.CrossRefPubMedPubMedCentral

73.

Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:330–5. https://doi.org/10.1016/j.cgh.2014.07.041.CrossRefPubMed

74.

Wilkinson N, Tsakok T, Dand N, BSTOP Study Group PSORT Consortium, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Investig Dermatol. 2019;139:115–23. https://doi.org/10.1016/j.jid.2018.07.028.CrossRefPubMed

75.

Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151:616–22. https://doi.org/10.1001/jamadermatol.2014.5479.CrossRefPubMed

76.

Van den Berghe N, den Keyser ED, Soenen R, et al. Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. Br J Dermatol. 2020;182:390–7. https://doi.org/10.1111/bjd.18016.CrossRefPubMed

77.

Soenen R, Meulewaeter E, Grine L, et al. Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step toward personalized therapy. J Investig Dermatol. 2019;139:2232–3223. https://doi.org/10.1016/j.jid.2019.04.012.CrossRefPubMed

78.

Pan S, Tsakok T, Dand N, BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium, et al. Using real-world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic-pharmacodynamic study. Clin Transl Sci. 2020;13:400–9. https://doi.org/10.1111/cts.12725.CrossRefPubMedPubMedCentral

79.

Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39–42. https://doi.org/10.1111/j.1346-8138.2012.01679.x.CrossRefPubMed

80.

Tourdot S, Abdolzade-Bavil A, Bessa J, et al. 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. mAbs. 2020. https://doi.org/10.1080/19420862.2020.1725369.CrossRefPubMedPubMedCentral

81.

Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241–53. https://doi.org/10.1007/s40259-019-00355-4.CrossRefPubMed

82.

Murdaca G, Negrini S, Greco M, Schiavi C, Giusti F, Borro M, et al. Immunogenicity of infliximab and adalimumab. Expert Opin Drug Saf. 2019;18:343–5. https://doi.org/10.1080/14740338.2019.1602117.CrossRefPubMed

83.

Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693–6. https://doi.org/10.1136/annrheumdis-2015-208684.CrossRefPubMed

84.

van der Zee HH, Gulliver WP. Medical treatments of hidradenitis suppurativa: more options, less evidence. Dermatol Clin. 2016;34:91–6. https://doi.org/10.1016/j.det.2015.08.006.CrossRefPubMed

85.

Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76:215–29. https://doi.org/10.1007/s40265-015-0516-5.CrossRefPubMed

86.

Maarouf M, Clark AK, Lee DE, Shi VY. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatol Treat. 2018;29:441–9. https://doi.org/10.1080/09546634.2017.1395806.CrossRef

Title: Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
Authors: Tasnim Abdalla
Michelle A. Lowes
Nirmal Kaur
Robert G. Micheletti
A. Hillary Steinhart
Afsaneh Alavi
Publication date: 01-03-2021
Publisher: Springer International Publishing
Keywords: Infliximab
Chronic Inflammatory Bowel Disease
Adalimumab
Acne Inversa
Published in: American Journal of Clinical Dermatology / Issue 2/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00579-z

At a glance: The STEP trials

Springer Medicine

Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

Pediatric Mastocytosis: Recognition and Management

Laser-Induced Chrysiasis: A Unique Adverse Event Associated With Q-Switched Lasers

Reply to: Cohen and Ross: “Laser-Induced Chrysiasis: A Unique Adverse Event Associated with Q-Switched Lasers”

The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World

Isotretinoin and Risk of Cardiovascular Events in Adults with Acne: A Population-based Retrospective Cohort Study